logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
November 9, 2024

Modifi Biosciences Acquired by Merck

by info@virtueinsight.comNews0 Comments

 

Modifi Biosciences, a leader in the development of direct DNA modification enabled cancer therapeutics, had announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada.

“In founding Modifi Biosciences, we sought to radically change the oncology treatment paradigm for cancer patients with glioblastoma and other tumors,” said Ranjit S. Bindra, MD, PhD, Modifi Biosciences Co-founder, Harvey and Kate Cushing, Professor of Therapeutic Radiology at Yale School of Medicine, and Scientific Director of the Yale Brain Tumor Center at Smilow Cancer Hospital. “We are honored to have Merck recognize the potential of our science, and as an oncology company, they are perfectly positioned to advance our innovations through clinical trials and commercialization.”

“DNA repair defects are a frequent hallmark of tumor cells and a major cause of resistance to cancer therapy,” said Dr. David Weinstock, vice president, discovery oncology, Merck Research Laboratories. “The talented Modifi Biosciences team has developed an innovative approach that we believe has potential for treating some of the most refractory cancer types.”

Under the terms of the agreement Merck, through a subsidiary, has acquired all outstanding shares of Modifi Biosciences for $30 million upfront. Modifi Biosciences shareholders are also eligible to receive potential milestone payments totaling up to $1.3 billion.

Visit our upcoming pharma conferences – https://virtueinsight.com/upcoming-conferences/

anticounterfeiting biosimilars biotech biotechnology clinicaltrials Counterfeit healthcare pharma pharmaceutical pharmacovigilance pharmaindustry pharmareglatory serialazation supplychain
prev

Lundbeck to buy Longboard Pharmaceuticals for $2.6bn

next

AbbVie to Acquire Aliada Therapeutics

RELATED POSTS

June 5, 2023
News

Spanish packaging firm Inden Pharma to expand footprint in India

read more
February 14, 2023
News

EyePoint to sell YUTIQ to Alimera Sciences

read more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

logotype

We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry.

Facebook-fTwitterYoutubeLinkedin-inInstagramPinterest

Quick Links

About us
Contact us
Event Support
Careers
Privacy Policy
Terms & Conditions

Subscribe to our newsletter

    © 2025 Virtue Insight. All rights reserved.